Pre-emptive antiviral therapy based on the early detection of CMV infection is an important strategy for the prevention of CMV disease following allogeneic BMT. Accepted methods for early detection of CMV infection include viral culture of blood or bronchial lavage specimens or CMV pp65 antigenemia testing of peripheral blood specimens. We describe a patient with aplastic anemia with worsening liver transaminases after allogeneic bone marrow transplantation who had repeated negative tests for CMV pp65 antigenemia despite positive viral blood cultures. Re-examination of peripheral blood samples with a different pp65 antibody pool revealed the presence of high levels of CMV in peripheral blood leukocytes, confirming a lack of reactivity to the original antibody pool. Following institution of antiviral therapy, a prompt reduction in the number of pp65 antigen-positive peripheral blood leukocytes paralleled a reduction in abnormal transaminases. The practical implications of these findings are discussed. Keywords: CMV infection; CMV pp65 antigenemia; BMT In 1988, van der Bij et al 1 reported that active CMV infection could be diagnosed by direct staining of peripheral blood leukocytes with monoclonal antibodies. Since that time, CMV pp65 antigenemia testing has been confirmed in many reports to be more sensitive than culture and has an assay time of about 5 h, compared with 1-4 weeks for CMV culture.
Summary:
Pre-emptive antiviral therapy based on the early detection of CMV infection is an important strategy for the prevention of CMV disease following allogeneic BMT. Accepted methods for early detection of CMV infection include viral culture of blood or bronchial lavage specimens or CMV pp65 antigenemia testing of peripheral blood specimens. We describe a patient with aplastic anemia with worsening liver transaminases after allogeneic bone marrow transplantation who had repeated negative tests for CMV pp65 antigenemia despite positive viral blood cultures. Re-examination of peripheral blood samples with a different pp65 antibody pool revealed the presence of high levels of CMV in peripheral blood leukocytes, confirming a lack of reactivity to the original antibody pool. Following institution of antiviral therapy, a prompt reduction in the number of pp65 antigen-positive peripheral blood leukocytes paralleled a reduction in abnormal transaminases. The practical implications of these findings are discussed. Keywords: CMV infection; CMV pp65 antigenemia; BMT In 1988, van der Bij et al 1 reported that active CMV infection could be diagnosed by direct staining of peripheral blood leukocytes with monoclonal antibodies. Since that time, CMV pp65 antigenemia testing has been confirmed in many reports to be more sensitive than culture and has an assay time of about 5 h, compared with 1-4 weeks for CMV culture. 2 In addition, CMV antigenemia is often detectable earlier in the course of infection than infectious virus. 2, 3 Although the early diagnosis of infection by culture-based techniques has resulted in reductions in the incidence of CMV disease and CMV-related mortality, a significant number of patients still develop disease when monitored in this fashion. 4, 5 CMV antigenemia assays have, therefore, been used increasingly to monitor patients after allogeneic transplantation.
In this report, we describe a marrow recipient who developed probable CMV hepatitis with repeatedly negative CMV antigenemia results despite the rapid isolation of infectious CMV by conventional culture. Restaining of peripheral blood leukocytes with a different pp65 monoclonal antibody pool revealed high levels of CMV antigenemia, indicating a lack of reactivity to the initially employed monoclonal antibody pool. To the best of our knowledge, this observation has not been previously reported.
Case report
A 28-year-old male presented to another institution in May 1996 with spontaneous ecchymoses on the trunk and extremities. The WBC was 1000/mm ) and CsA 1.5 mg/kg i.v. every 12 h beginning 7 days prior to transplantation. GVHD prophylaxis consisted of CsA and MTX. Post-transplant complications included pseudomonas cellulitus and bacteremia, mild veno-occlusive disease of the liver and grade I GVHD.
CMV antigenemia and conventional culture testing were performed weekly starting on day +14. Between day +47 and day +54 the serum transaminases rose sharply. On day +54, CMV was isolated from two blood cultures obtained 7 and 13 days earlier ( Figure 1 ). Ganciclovir, 5 mg/kg twice daily and IVIG 400 mg/kg every other day were administered, with improvement in liver function studies. Further cultures remained negative for CMV. Following a 3-week course of induction, once daily ganciclovir and weekly IVIG were continued until day +104. The patient remains well Ͼ180 days post-transplantation with repeatedly negative blood cultures for CMV. 
Materials and methods

Patient samples
Five to 10 ml of blood collected in EDTA were submitted weekly to the Clinical Virology Laboratory for the detection of CMV infection. Blood samples were routinely tested by both conventional culture and CMV antigenemia assay as described below.
Culture methods
CMV cultures were performed as previously described. 6 In brief, leukocytes were separated in 6% dextran, inoculated into two human diploid fibroblast roller tubes and observed for cytopathic effects for 3 weeks. Virus isolates were identified by passage of cell suspensions into shell vial cultures followed by staining with monoclonal antibody to CMV immediate-early p72 antigen (Dupont NEN, Boston, MA, USA).
CMV antigenemia assay
Biotest CMV Brite Test was routinely performed according to the manufacturer's instructions (Biotest Diagnostics, Denville, NJ, USA). Briefly, leukocytes were separated using dextran solution and counted in a hemacytometer. After adjusting the cell concentration to 1.5 × 10 6 /ml, 100 l was centrifuged using a cytospin (Shandon, Pittsburgh, PA, USA) on to each of three slides per specimen. Leukocytes were then fixed and permeabilized with reagents provided, and two slides were stained with anti-CMV pp65 (C10/C11) monoclonal antibodies followed by staining with FITC-labeled rabbit anti-mouse IgG conjugate with Evans blue. Positive and negative control slides were included in every test run. Slides were then examined under a fluorescence microscope at ×250 magnification. Positive cells, predominantly neutrophils, were identified by characteristic homogeneous green nuclear fluorescence. The number of positive cells was recorded for each slide. A positive result consisted of one or more CMV antigen-positive cells per duplicate stain. Results were expressed as the sum of positive cells on two slides. Slides were kept at 4°C and re-read by additional readers if discrepancies were noted between CMV antigenemia and CMV culture results. In such cases the third slide was also stained and examined.
Bartels CMV antigenemia test: The patient's slides, previously stained with Biotest reagents, were immersed in PBS. Coverslips were gently removed and the slides were rinsed. Slides were then restained with the CINA antibody pool and conjugate (Argene Biosoft CINA kit from Bartels, Issaquah, WA, USA) and re-examined for the presence of CMV pp65-positive leukocytes.
Results
Serial blood samples were repeatedly negative for CMV antigenemia using Biotest reagents (Figure 1 ). However, CMV was isolated from the three samples obtained prior to the initiation of ganciclovir therapy. Cultures for samples submitted on days +47 and +54 were positive within the first week after inoculation, indicating a high viral load. Reexamination of C10/C11 stained slides and staining of a third slide confirmed the absence of pp65-positive leukocytes. However, re-staining of the same slides with the CINA pp65 monoclonal antibody pool revealed numerous positively stained cells. The patient's CMV isolate and a control CMV strain (the stock of a clinical isolate that was known to be pp65 positive) were also inoculated into cell culture and the infected cells were stained at various times after infection with pp65 antibody pool from the Biotest kit and CMV immediate-early p72 antibody. Staining by the Biotest antibody pool was negligible for the CMV strain isolated from the patient and positive for the control strain, while staining for p72 was comparable between the strains.
Discussion
CMV antigenemia assays have had a significant impact on the rapid and early detection of CMV infection in immunocompromised hosts. Nevertheless, the current report indicates that the most widely used antigenemia test has limitations. Monoclonal antibody preparations may be too specific and may not detect some wild-type virus strains. 7 To minimize this risk, the Bartels reagent contains a pool of two antibodies (1C3, AYM-1) to two different CMV pp65 epitopes. The Biotest CMV pp65 reagent also contains two antibodies to pp65 (C10 and C11), however, it has not been reported whether the two epitope targets of C10 and C11 are different. A comparison of the Biotest (C10,C11) kit to an earlier Biosoft test kit utilizing the 1C3 antibody alone suggested that the 1C3 antibody is more sensitive, more frequently detecting low level antigenemia. 8 In patients with higher level antigenemia, however, false negative antigen tests did not occur with either antibody preparation. Gerna et al 9 also compared the C10, C11 antibodies to a pool of three pp65 antibodies that included 1C3 and reported similar findings. However, a subsequent multisite study involving four laboratories and over 500 blood samples found the Biotest kit (C10/C11 antibodies) and the Biosoft kit (CINA pool) to be similar in sensitivity. 10 Discrepancies between culture and antigenemia tests can occur for a number of reasons. The presence of CMV anti-genemia with negative cultures is not unusual since the sensitivity of antigen testing exceeds conventional culture techniques. 2, 6 This may occur early in the course of infection, when viral burden is low, or after initiation of antiviral therapy, which inhibits replication and isolation of the virus. 6 In our laboratory, 94-96% of blood samples positive for CMV by either method are positive by pp65 antigenemia, whereas only 56-60% are culture positive. The 4-6% of samples that are culture positive but antigenemia negative are characterized by low levels of virus, with cultures requiring 2-3 weeks to become positive. In contrast, the rapid isolation of CMV in this patient indicated a high viral burden and the repeatedly negative antigenemia testing reflected a lack of reactivity to the C10/C11 antibodies in this particular CMV strain.
End-organ involvement with CMV may not be suspected in patients with negative antigenemia tests. The diagnosis of CMV hepatitis, in particular, is difficult to make following allogeneic BMT given the nonspecific nature of the signs and symptoms of hepatic disease and the difficulty in obtaining liver tissue for definitive diagnosis. 11 We believe it is likely that this patient had CMV hepatitis based on the temporal relationship of the viremia to the abnormal transaminases and the rapid response to antiviral therapy.
In conclusion, the CMV pp65 antigenemia test has been a tremendous advance in the rapid detection of active CMV infection in the blood. The ability to rapidly assess viral load is of great benefit in both deciding whether to treat and in monitoring response to therapy. Nevertheless, it is important not to exclude the possibility of CMV end-organ disease based solely on negative CMV antigenemia. CMV pp65 antigenemia can be negative due to technical error, reagent degradation, end-organ involvement without viremia, or as in the present case, to lack of reactivity to the pp65 antibody pool used. Although probably not cost effective, continuing to use culture backup of antigenemia serves as a cross-check and allows detection of test failures. This is the first reported case of lack of reactivity to CMV pp65 antigenemia with the C10/C11 pool and serves as a reminder that monoclonal antibody assays on which we depend may sometimes fail to detect a wild-type strain. Repeating the assay with another antibody pool may allow detection in cases where CMV disease is suspected.
